Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).
Komrokji R, Santini V, Zeidan A, Sekeres M, Fenaux P, Raza A, Mittelman M, Thepot S, Buckstein R, Germing U, Madanat Y, Diez-Campelo M, Valcárcel D, Jonasova A, Shah S, Xia Q, Sun L, Navada S, Savona M, Platzbecker U. Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS). Journal Of Clinical Oncology 2025, 43: 6569-6569. DOI: 10.1200/jco.2025.43.16_suppl.6569.Peer-Reviewed Original ResearchLower-risk myelodysplastic syndromesErythropoiesis-stimulating agentsHematological improvement-erythroidRBC-TIHypomethylating agentsTransfusion burdenClinical activityInternational Working GroupTransfusion-DependentTransfusion reductionData cutoff dateRBC transfusion independenceFirst-in-classPooled dataEffect of prior treatmentHb riseMyelodysplastic syndromeMedian durationPhase 2/3Clinical benefitSafety profileLenalidomideActive dosesImetelstatEfficacy data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply